Jubilant Pharmova Reports Q3 & 9M’FY26 Results: Revenue Growth of 17%, EBITDA Margins to Expand in CDMO Sterile Injectables Business

Jubilant Pharmova Ltd. has reported its Q3 & 9M’FY26 results. The company's revenue grew by 17% on a YoY basis, driven by incremental revenue generation from the new & third line in CDMO Sterile Injectable business. EBITDA for the period grew by 5% YoY to Rs. 310 Cr. due to improved performance in CDMO Sterile Injectables and CRDMO business. The company is investing in Radiopharma, CDMO Sterile Injectables and CRDMO business to secure future growth, resulting in a net debt/EBITDA ratio of 1.3x in Dec’25. The company expects EBITDA margins to strengthen going forward, effectively offsetting higher depreciation costs and driving net profit growth.